# Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer

> **NCT02139579** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 24 (estimated)

## Conditions studied

- Lung, Carcinoma

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT02139579
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-05
- **Primary completion:** 2015-12
- **Final completion:** —
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2014-05-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02139579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02139579, "Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02139579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*